Company Filing History:
Years Active: 2017-2019
Title: Innovations of Chung-Ling Liang in Myopia Treatment
Introduction
Chung-Ling Liang is a notable inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of ophthalmology, particularly in the treatment and prevention of myopia. With a total of 2 patents, his work focuses on innovative therapeutic approaches that leverage the power of microRNA.
Latest Patents
Liang's latest patents include a composition and therapeutic use of anti-sense microRNA-328. This invention is directed towards oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The pharmaceutical composition comprises the anti-sense microRNA-328 and a pharmaceutically acceptable carrier. Furthermore, he has developed a method for preventing or treating myopia by administering the anti-sense microRNA-328 composition, preferably through topical administration to the eyes. Another significant patent involves a method for treating and/or preventing myopia, which includes administering an RNA interference (RNAi) capable of counteracting another RNA interference that inhibits the expression of the PAX-6 gene.
Career Highlights
Chung-Ling Liang is affiliated with Kaohsiung Medical University, where he continues to advance research in the field of myopia treatment. His innovative approaches have garnered attention in the scientific community, contributing to the understanding and management of this common vision condition.
Collaborations
Liang has collaborated with esteemed colleagues such as Suh-Hang Hank Juo and Edward Hsi, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Chung-Ling Liang's contributions to the field of myopia treatment through his innovative patents highlight the importance of research in developing effective therapeutic solutions. His work continues to pave the way for advancements in ophthalmology.